stonks4u
Sign up free
GRCE logo

GRCE Grace Therapeutics, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$2.16
+0.09 (+4.35%)

Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betametha…

Market Cap: $35.15Mwww.gracetx.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

100
100
Aug 13Aug 13

Quote

Day Range
$2.02 – $2.19
52-Week Range
$1.79 – $5.18
Volume
$397.6K
Market Cap
$35.15M
50-Day Avg
$2.29
200-Day Avg
$3.14
Prev Close
$2.07
Open
$2.03

Valuation & Ratios

P/E Ratio
-9.85
EPS
$-0.47
P/B Ratio
1.20
P/S Ratio
0.00
Debt/Equity
0.00
Current Ratio
8.10
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-12.2%
Return on Assets
-11.7%
FCF Yield
-11.6%
EV/EBITDA
-5.37

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2026$0.00$-7.79M$-0.47
2025$0.00$-13.63M$-1.13
2024$0.00$-17.44M$-1.83
2023$0.00$-57.39M$-7.72
2022$0.00$-12.27M$-2.02

Social Signal Score

50
5d
50
1 mentions
—
30d
50
1 mentions
—
60d
50
1 mentions
—
90d
50
1 mentions
—
news: 1

Earnings

Thu, Nov 12(in 3 months)

Consensus estimate $-0.13 per share

3of 7 quarters beat consensus

Typical surprise -8.3% (median, so one quarter with a near-zero estimate can't distort it)

  • Thu, Aug 13$-0.91 vs $-0.13miss
  • Thu, Jun 18$-0.07 vs $-0.24beat
  • Thu, Feb 12$-0.14 vs $-0.09miss
  • Thu, Nov 13$-0.15 vs $-0.12miss
  • Tue, Aug 12$-0.21 vs $-0.22beat
  • Mon, Jun 23$0.06 vs $-0.20beat

Estimates and results for GRCE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

GRCEhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsglobenewswire.com·2d ago·Neutral

    …peutics Announces First Quarter 2027 Financial Results, Provides Business Update PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights for the three months en…

    View source ↗